The Wire. The Letter. The Clock.

Three technologies. Spring 2026. Witnessed without commentary.

The Wire — A paralyzed patient moves a robotic arm through thought alone. Neuralink's N1 chip threads 1,024 electrodes into motor cortex. The signal leaves the body and returns as motion. Something irreversible has begun at the boundary between nerve and machine.

The Letter — A single injection. One corrected letter in three billion. In a Phase 3 trial, Intellia's NTLA-2001 achieves 87% efficacy against transthyretin amyloidosis — the most successful in-vivo gene edit ever recorded in a human. Profluent and Eli Lilly announce a $2.25 billion partnership to train AI models that write entirely new gene editors from scratch. The genome is no longer fixed.

The Clock — Life Biosciences enrolls the first human subjects in ER-100, the world's first partial epigenetic reprogramming trial in living people. Altos Labs' $3 billion program moves toward the clinic. The clock inside each cell — the one that counts toward death — may be something we can now turn back.

This series does not explain. It observes. The transformation is already underway.

Technologies covered: Brain-computer interfaces (Neuralink N1, N2), in-vivo CRISPR gene editing (Intellia NTLA-2001), AI-designed gene editors (Profluent × Eli Lilly), epigenetic reprogramming (Life Biosciences ER-100, Altos Labs)

Research window: March–May 2026 developments with evergreen scientific context